Health
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than those with normal histology LSEC capillarization observed in patients was strongly associated with liver fibrosis and to
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH ","length":257,"tagName":"p"}]},{"val":[{"type":"text","content":"In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than those with normal histology ","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"LSEC capillarization observed in patients was strongly associated with liver fibrosis and to a lesser extent inflammation","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"End of treatment biopsies from Phase 2b NATIVE showed improvement in LSEC capillarization in patients with MASH and treated with lanifibranor compared to placebo","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"In addition, using two preclinical models, lanifibranor demonstrated effects extending beyond capillarization reversal, normalizing portal pressure and intrahepatic vascular resistance","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"These effects in the preclinical models appear more pronounced than those observed with single PPAR agonists, suggesting that as a pan-PPAR agonist, lanifibranor could represent a comprehensive therapeutic approach for MASH, fibrosis regression, and the prevention of progression to cirrhosis","length":292,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1163,"olType":false},{"type":"text","content":" Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the...